Session Abstract – PMWC 2022 Silicon Valley

 Session Chair Profile

Ph.D., Assistant Professor, UCSF

Biography
Dr. Paulk is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing for numerous rare diseases and cancer, directed evolution to evolve novel viral capsids, and comparative multiomic approaches to interrogate translational AAV biology. Dr. Paulk is a global KOL in gene therapy and consults extensively for big pharma, and sits on the SABs for Sarepta, Astellas, Dyno, CEVEC, Excision Bio, Whitelab Genomics, and the John's Hopkins Gene Therapy Initiative. She is regularly quoted in STAT, Endpoints, Phacilitate, GEN, Biopharma Dive, Wall Street Journal, and is a frequent guest on Biotech Clubhouse. Dr. Paulk sits on the Scientific Editorial Boards of the journals Nature Gene Therapy and Human Gene Therapy, and is extensively involved in numerous committees within the American Society of Gene & Cell Therapy.


 Speaker Profile

M.D., Ph.D., Professor of Pediatrics, Stanford University School of Medicine

Biography
Matthew Porteus is the Sutardja Clark Professor of Definitive and Curative Medicine in the Department of Pediatrics and Institute of Stem Cell Biology and Regenerative Medicine at Stanford. He is the co-Director for the Stanford Center for Definitive and Curative Medicine (CDCM). His primary research focus is on developing genome editing as an approach to cure disease, particularly those of the blood and immune system (including sickle cell disease) and other organ systems. His goal is to combine his research and clinical interests to develop innovative curative therapies. His dream is to one day develop gene editing so that patients are cured of their disease before they or their parents even knew they had it. He served on the 2017 National Academy Study Committee of Human Genome Editing and currently serves on the Scientific Advisory Board for WADA on Cell and Gene Doping and the NIH NExTRAC advisory committee evaluating the emergence of new technologies.


 Speaker Profile

M.D., Ph.D., Chief Scientific Officer, 4D Molecular Therapeutics

Biography
Peter Francis, M.D., Ph.D., served as our Chief Medical Officer January 2019 through February 2020 before becoming our Chief Scientific Officer. Dr. Francis previously served as our Senior Vice President, Clinical Translational R&D, and Retina Therapeutic Area Head from August 2018 to January 2019. Dr. Francis previously served as Chief Medical Officer at RetroSense Therapeutics from February 2012 until August 2016 when it was purchased by Allergan Inc. Dr. Francis practices as a physician at Orion Eye Center. Dr. Francis received his B.Sc. in Molecular Cell Biology from the University of Southampton, England in 1991. He earned his M.D. from the University of Southampton, England in 1992. He earned his Ph.D. in ophthalmic genetics from University College, London in 2000.


 Speaker Profile

PHD, Co-Founder and SVP, Forge Biologics

Biography
Dr. De Silva is an experienced scientist and entrepreneur, with more than a decade of experience in discovery research, therapeutic development, and partnering across oncology, infectious disease, and gene therapy. Prior to founding Forge, she held RD and leadership roles in both academic and industry settings, including at Genentech, Ohio State University and Myonexus Therapeutics.


 Speaker Profile

Ph.D., Chief Scientific Officer, Q2 Solutions

Biography
Dr. Patrice Hugo is responsible for the medical affairs and scientific activities for the Central Laboratories, and Specialty Testing Centers of Excellence worldwide including the Expression Analysis Genomics, Vaccine, Biomarkers Translational Science and Innovation Laboratory and BioAnalytical/ADME laboratories. Prior to joining Q² Solutions, Dr. Hugo was Associate Vice President and Chief Clinical Trial Scientist at LabCorp/Covance Central Lab Division and Chief Scientific Officer at Clearstone Central Lab acquired by LabCorp. Previously, he worked at Caprion (now CellCarta) as Executive Vice President R&D, and Principal Investigator at the Montreal Clinical Research Institute with academic affiliation at McGill University and University of Montreal. Dr. Hugo obtained his Ph.D. in Experimental Medicine & Immunology at McGill University and held post-doctoral positions at the Walter and Eliza Hall Institute, Australia, and the Howard Hughes Medical Institute, USA. He is author or co-author of over 75 scientific manuscripts and has over 25 years of biomarker experience.